Finch Therapeutics Group, Inc.

1.80 USD
+0.46 (+34.33%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Finch Therapeutics Group, Inc. stock is down -7.22% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 June’s closed higher than May.

About Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection. It is also developing FIN-211 and TAK-524, which are orally administered targeted consortia product candidates.